

# Aequus Pharmaceuticals Inc.

00:39 17 Oct 2020

## Aequus extends commercial agreement with Sandoz for transplant therapy tacrolimus in Canada

Aequus Pharmaceuticals Inc (CVE:AQS) (OTCQB:AQSZF) (FRA:AEQ) said on Friday that it has agreed to an extension of terms for its promotional service agreement on the Sandoz drug tacrolimus immediate-release (tacrolimus IR), which is used to prevent patient rejection after organ transplants.

The Vancouver-based company said that it has extended its commercial agreement on tacrolimus with Sandoz Canada Inc to December 31, 2021. A trio of drugs including tacrolimus currently form the core of the Canadian company's business.

In December 2015, Aequus said it began promoting Sandoz's generic tacrolimus, a transplant therapy which aims to treat and prevent acute rejection following an organ transplant. Tacrolimus has since achieved "over 10x growth" in Canada through increased brand awareness and new patient adoption programs, according to the company.

### READ: Aequus Pharmaceuticals has the right Rx to bring new drugs to the Canadian market

"We believe there continues to be considerable room for growth over the next 12 months for tacrolimus IR, as we plan continued support for patients and physicians regarding the use of this high-quality and cost-effective alternative to branded tacrolimus," Aequus Pharmaceuticals CEO Doug Janzen said in a statement.

Janzen said the extension is "particularly meaningful" as it reaffirms Aequus' commercial capabilities across specialties, "from market access and reimbursement to sales force execution," which is a key driver of growth in the pharma business.

"Sandoz has been a fantastic partner and while we continue to talk to them about Vistitan and other potential products, this extension allows us to seamlessly continue our efforts on Tacrolimus IR while our Eye Care team focus on the launches of the Evolve products," added Janzen.

Vistitan, which reduces the pressure inside the eyes of patients with glaucoma was first marketed by the pharma giant Sandoz.

Medicom's Evolve line of preservative-free, dry-eye products is a preservative-free prescription product for the treatment of open-angle glaucoma.

Contact the author Uttara Choudhury at [uttara@proactiveinvestors.com](mailto:uttara@proactiveinvestors.com)

Follow her on Twitter: @UttaraProactive

**Price:** 0.125

**Market Cap:** \$13.99 m

### 1 Year Share Price Graph



### Share Information

**Code:** AQS

**Listing:** TSX-V

**52 week High Low**  
0.155 0.065

**Sector:** Pharma & Biotech

**Website:** [www.aequuspharma.ca](http://www.aequuspharma.ca)

### Company Synopsis:

*Aequus Pharmaceuticals Inc. is a growing specialty pharmaceutical company focused on developing and commercializing high quality, differentiated products.*

[action@proactiveinvestors.com.au](mailto:action@proactiveinvestors.com.au)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 [action@proactiveinvestors.com.au](mailto:action@proactiveinvestors.com.au)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Aequus Pharmaceuticals Inc. named herein, including the promotion by the Company of Aequus Pharmaceuticals Inc. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).